Appraising the value of CircRNAs for the diagnosis and prognosis of esophageal squamous cell cancer: An updated meta-analysis

• Published in: Pathology, research and practice Vol. 254; p. 155074
• Main Authors: Du, Lihong, Yang, Jianzhou, Qin, Shaoze, Ding, Shuyu, Guo, Yuwei, Wang, Jinsheng
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01.02.2024
• Subjects: Biomarkers, Tumor - genetics; Circular RNAs; Diagnosis; Esophageal cancer; Esophageal Neoplasms - diagnosis; Esophageal Neoplasms - genetics; Esophageal Neoplasms - mortality; Esophageal Neoplasms - pathology; Esophageal Squamous Cell Carcinoma - diagnosis; Esophageal Squamous Cell Carcinoma - genetics; Esophageal Squamous Cell Carcinoma - pathology; Humans; Meta-analysis; Prognosis; RNA, Circular - genetics; Prognosis; Diagnosis; Circular RNAs; Esophageal cancer; Meta-analysis
• ISSN: 0344-0338; 1618-0631; 1618-0631
• DOI: 10.1016/j.prp.2023.155074

The purpose of this study was to thoroughly assess the relevance of circular RNAs (circRNAs) in the diagnosis and prognosis of esophageal squamous cell carcinoma (ESCC)， and design a systematic review and meta-analysis. Using Stata 14.0 software, a meta-analysis was carried out by looking for pertinent studies up to February 20, 2023, in the online databases PubMed, Embase, Web of Science, and CNKI. The clinicopathologic and prognostic data were evaluated using the combined advantage ratio (OR) and combined hazard ratio (HR), respectively. The threshold effects and publication bias were quantified using Spearman's correlation and the Deeks funnel plot asymmetry tests, respectively. A total of 36 pertinent studies with a literature quality score of 7 or above were included in this study. Of them, 22 papers dealt with clinicopathological characterization, 15 dealt with prognostic analysis, and 13 dealt with diagnostic analysis. The findings demonstrated that high expression of upregulated circRNAs was associated with worse clinicopathological features (tumor size: OR=3.61, 95% CI:1.45–5.78; TNM stage: OR=2.12, 95% CI:1.41–2.83; lymph node metastasis: OR=2.87, 95% CI:1.67–4.07) and worse OS (HR=1.49, 95% CI:1.26–1.77). High downregulated circRNAs expression was linked to improved clinicopathologic characteristics (TNM staging: OR=0.35, 95% CI:0.13- 0.95) and longer survival (HR=0.48, 95% CI:0.27–0.84); combined sensitivity was 0.77 (95% CI: 0.71–0.82), specificity was 0.80 (95% CI:0.74–0.86), and area under the subject operating characteristic curve (AUC) was 0.86 (95% CI:0.82- 0.88). CircRNAs are useful for ESCC patient diagnosis and prognosis, and they are anticipated to be unique potential biomarkers for ESCC clinical diagnosis.